Biodesix (BDSX) Form 4: 31 shares vested; 13 sold at $7.62

Biodesix (BDSX) reported a routine insider transaction for Chief Accounting Officer Chris Vazquez.

Accepted by SEC EDGAR 11/13/2025 - 04:54 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Biodesix (BDSX) reported a routine insider transaction for Chief Accounting Officer Chris Vazquez. On 11/10/2025, 31 shares of common stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes upon vesting, 13 shares were automatically sold at $7.62. Following these transactions, Vazquez directly owned 936 shares. Each RSU represents one share of common stock, and the RSUs vest in sixteen successive quarterly installments measured from February 8, 2022 and have no expiration date.

Insights

Equity compensation analyst

Routine RSU vesting with tax sale; neutral impact.

The activity reflects standard equity compensation mechanics: 31 shares delivered from RSU vesting and an automatic sale of 13 shares at $7.62 to satisfy tax obligations. These figures are adjusted for the one-for-twenty reverse split effective September 15, 2025.

Post-transaction, the officer holds 936 shares directly and 29 RSUs remain outstanding. The RSUs vest in a series of sixteen quarterly installments measured from February 8, 2022. Cash-flow and market impact are minimal given the small share counts and administrative nature.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Vazquez Chris

Role Chief Accounting Officer

Sold 13 shs ($99.06)

Approx. gross sale proceeds $99.06

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	31	$0.00	$0.00
Exercise	Common Stock	31	$0.00	$0.00
Sale	Common Stock	13	$7.62	$99.06

Holdings After Transaction: Restricted Stock Units — 29 contracts (Direct); Common Stock — 936 shares (Direct)

Footnotes (4)

1. F1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
2. F2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
4. F4. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biodesix (BDSX) disclose in this Form 4?

An officer received 31 shares from RSU vesting on 11/10/2025 and sold 13 shares at $7.62 to cover taxes.

How many Biodesix (BDSX) shares does the reporting person own after the transactions?

Following the transactions, the reporting person directly owned 936 shares.

What is the status of the RSUs for Biodesix (BDSX)?

The officer has 29 RSUs remaining; each RSU equals one share and vests in sixteen quarterly installments measured from February 8, 2022.

Why were 13 Biodesix (BDSX) shares sold at $7.62?

The 13 shares were sold automatically to cover taxes upon the RSU vesting.

How did the reverse stock split affect the reported amounts for Biodesix (BDSX)?

All figures reflect the one-for-twenty reverse stock split effective September 15, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazquez Chris

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		M		31(1)	A	(2)	949(1)	D
Common Stock	11/10/2025		S(3)		13	D	$7.62	936	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	11/10/2025		M			31(1)	(4)	(4)	Common Stock	31(1)	$0	29(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

2. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

3. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

4. These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.